The Effects of All-Trans Retinoic Acid on the Induction of Oral Tolerance in a Murine Model of Bronchial Asthma

Hirotaka Sakamoto, Toshiyuki Koya, Keisuke Tsukioka, Kenjiro Shima, Satoshi Watanabe, Hiroshi Kagamu, Yosuke Kimura, Takuro Sakagami, Takashi Hasegawa, Eiichi Suzuki, Ichiei Narita

Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University Graduate School of Medical and Dental Sciences, and Department of General Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan

Key Words
All-trans retinoic acid · Bronchial asthma · Oral tolerance · Regulatory T cell

Abstract
Background: Active suppression induced by regulatory T (Treg) cells is reported to be one of the mechanisms involved in oral tolerance. All-trans retinoic acid (ATRA) has been reported to affect Treg cell differentiation. The present study examined the effects of ATRA on the induction of oral tolerance in a murine model of bronchial asthma. Methods: BALB/c mice were sensitized to and challenged with ovalbumin (OVA) through feeding followed by OVA challenges. In some study groups ATRA was orally administered concomitantly with OVA feeding either in the presence or absence of the retinoic acid receptor antagonist LE135. Lung CD4+ T cells were isolated from mice exposed to ATRA and/or OVA, and transferred to control mice. Airway hyperresponsiveness (AHR), cell counts and cytokine levels in bronchoalveolar lavage (BAL) fluid, and lung histology were assessed. Results: Concomitant administration of ATRA with OVA ameliorated AHR, airway eosinophilia, elevation of cytokines in BAL fluid and goblet cell metaplasia. The proportion of Treg cells in the lungs was increased in mice treated with OVA and ATRA, as compared to those treated with OVA only. Transfer of lung CD4+ T cells from mice treated with OVA and ATRA induced suppression of AHR and airway inflammation. LE135 completely reversed the effects of ATRA on AHR, airway allergic inflammation and the number of Treg cells in the lungs. Conclusion: These data suggested that oral administration of ATRA with OVA had the potential to enhance oral tolerance in this murine model of bronchial asthma. These effects were mediated, at least in part, by Treg cell expansion.

Introduction
Bronchial asthma is characterized by recurrent episodes of airway obstruction, airway hyperresponsiveness (AHR) to environmental stimuli, acute-on-chronic airway inflammation and structural changes in the airway walls [1]. Therefore, asthma management is based on avoiding exposure to allergens and controlling airway in-
flammation. Currently, inhaled corticosteroids (ICS) are the most potent agents used to suppress airway inflammation. Indeed, there is substantial evidence for the efficacy of ICS in reducing airway inflammation [2], ameliorating AHR [3], airway remodeling [4], alleviating clinical symptoms [5] and improving prognosis [6]. However, several reports have indicated that ICS has little influence on disease history, even if disease severity is controlled [7, 8]. Moreover, the cost of asthma management is increasing rapidly.

Allergen (antigen)-specific immunotherapy is an immune-modifying therapy that has been recommended for the treatment of allergic rhinitis, venom hypersensitivity, some drug allergies, and mild bronchial asthma [9]. Oral administration of antigen is classically used to induce antigen-specific systemic immunotherapy, and is termed oral tolerance [10, 11]. It is now widely accepted that the mechanisms of oral tolerance include not only anergy and apoptosis of antigen-specific T cells in the gut, but also active suppression through the induction of antigen-specific regulatory T (Treg) cells [12, 13]. Most of the induced Treg cells are characterized by abundant production of immunosuppressive cytokines, such as interleukin (IL)-10 and transforming growth factor-β (TGF-β), and expression of the transcription factor forkhead box P3 (Foxp3) [14].

We previously reported that both transfer of T helper (Th) 17 cells or administration of IL-17 in the induction phase of oral tolerance abolished the therapeutic effects of oral tolerance by upregulating IL-6 production in Peyrer’s patch (PP) in a murine asthma model [15]. The vitamin A metabolite, retinoic acid (RA), has also been reported to enhance the expression of α4β7 integrin and C-C chemokine receptor type 9 on T cells upon activation, imprinting them with gut tropism [16]. RA is a key regulator of TGF-β-dependent immune responses and was shown to inhibit IL-6-driven induction of proinflammatory Th17 cells and to promote anti-inflammatory Treg cell differentiation; peripheral conversion of CD4+ T cells to Treg cells occurred primarily in gut-associated lymphoid tissue after oral exposure to antigen [17]. We therefore hypothesized that oral administration of all-trans RA (ATRA) along with the antigen would have the potential to enhance the effects of oral tolerance.

In the present study, we investigated the effect of ATRA on the induction of oral tolerance in a murine airway allergy model. Following challenges with ovalbumin (OVA), we evaluated AHR and allergic inflammation. We also investigated the modulating effects of transfer of CD4+ T cells from mice treated with oral ATRA and OVA to animals that did not receive these compounds orally, and assessed whether the effects of ATRA were mediated through the RA receptor (RAR) by using the RAR antagonist LE135.

**Materials and Methods**

**Animals**

Eight-week-old female BALB/c mice free of murine-specific pathogens were purchased from CLEA Japan Inc. (Tokyo, Japan). The animals were housed under specific pathogen-free conditions with a 12:12 h light:dark cycle. All experiments were conducted under a protocol approved by the Niigata University ethics committee for animal experiments.

**OVA-Induced Allergic Airway Inflammation and Oral Tolerance**

Mice were sensitized on days 0 and 14 by intraperitoneal injection of 20 μg OVA premixed with 2.25 mg of Al(OH)3 in 100 μl of phosphate-buffered saline (PBS). After sensitization, the animals were exposed to an OVA aerosol (10 mg/ml in 0.9% saline) for 20 min on days 28, 29 and 30. From days 37 to 41 the mice were administered OVA (20 mg/day or 100 mg/day) by gavage once a day to induce oral tolerance, followed by OVA aerosol exposure (as described above) on days 48, 49 and 50. ATRA (250 μg/day) was administered orally along with OVA on days 37–41. Control mice received the same volume of PBS or ATRA alone by gavage. In some experiments, an RAR antagonist (LE135; 200 μg/day) was administered intraperitoneally (i.p.) with oral ATRA + OVA on days 37–41. Twenty-four hours after the final OVA challenge, AHR was assessed and specimens of bronchoalveolar lavage (BAL) fluid, serum and lungs were collected for further analysis. Figure 1 shows a summary of the experimental protocols used in this study. In some mice, PP specimens were obtained 24 h after the final OVA feeding.

**Cell Preparations from Lungs and PPs and Transfer of Lung Cells**

Lung cells were isolated as previously described [18] using collagenase digestion. Lung CD4+ T cells were purified from lung cells (purity >98%) using mouse CD4 Dynabeads® (Invitrogen, Carlsbad, Calif., USA). These lung CD4+ T cells were then administered intravenously (5 × 106 cells/mouse) to OVA-sensitized mice, followed by further OVA challenges (fig. 1).

PPs were resected from the small intestine, passed through a steel mesh to remove any aggregates, and then washed twice with PBS containing 0.2% BSA and 0.02% NaN3 before use for flow cytometry.

**Airway Responsiveness**

AHR was assessed by measuring changes in respiratory resistance in response to increasing doses of inhaled methacholine (MCh) using the Flexivent system (SCIREQ, Montreal, Que., Canada), as previously reported [19].

**BAL Fluid and Lung Histology**

Immediately after the measurement of AHR, BAL was performed via a tracheal tube, as previously described [20]. Lungs were fixed in 10% formalin and processed for paraffin embedding.

---

Int Arch Allergy Immunol 2015;167:167–176
DOI: 10.1159/000437326

Sakamoto et al.
Mucus-containing goblet cells were detected by staining the paraffin sections (5 μm thick) with periodic acid-Schiff (PAS). Histological analyses were performed as previously described [21].

**Flow Cytometry**

The surface phenotypes of the lung CD4+ T cells were analyzed by flow cytometry using a three-color immunofluorescence test. This employed monoclonal antibodies raised against CD4 (RM4–5), CD25 (PC61; both obtained from BD Biosciences, San Jose, Calif., USA) and Foxp3 (FJK-16S; eBioscience, San Diego, Calif., USA). After washing, the staining was analyzed on a FACSCalibur flow cytometer using CellQuest software (BD Biosciences).

**Measurement of Cytokines in BAL Fluid**

Supernatants from BAL fluid were stored at –80°C prior to the measurement of cytokines. Enzyme-linked immunosorbent assay (ELISA) kits for the detection of IL-4, IL-5 and IL-17 were obtained from eBioscience. IL-10 and IL-13 ELISA kits were purchased from R&D Systems (Minneapolis, Minn., USA).

**Statistical Analysis**

The Mann-Whitney U test was used to determine the significance of group differences. Data were pooled from three independent experiments with 4 mice per group in each experiment (n = 12). Comparisons for all pairs were performed using the Kruskal-Wallis test. Significance was assumed at p < 0.05 for all tests. Values for all measurements were expressed as the mean ± standard error of the mean (SEM).

**Results**

**Effect of ATRA on AHR, Airway Inflammation and Airway Remodeling**

We initially examined the effects of oral OVA administration in a murine airway allergy model. Mice that were treated with 100 mg/day OVA showed reduced AHR in response to MCh (fig. 2a), reduced airway eosinophilia (fig. 2b), lower levels of IL-5 and IL-13 in BAL fluid (fig. 2c), and reduced mucus production in the bronchi (fig. 2d, e) as compared with mice treated with PBS alone. On the other hand, 20 mg/day OVA did not induce a significant reduction of AHR, airway eosinophilia, Th2 cytokine production in BAL fluid and goblet cell metaplasia (fig. 2). However, administration of ATRA in addition to 20 mg/day OVA reduced AHR to a similar level to that
observed in animals administered 100 mg/day OVA (fig. 2a). Airway eosinophilia in the ATRA plus 20 mg/day OVA group was significantly decreased in comparison to the group that received OVA only (fig. 2b). The IL-5 and IL-13 levels in BAL fluid were decreased in mice that were treated with ATRA plus 20 mg/day OVA, as compared to mice receiving only 20 mg/day OVA only (fig. 2c). The number of PAS-positive cells was also significantly lower in the ATRA plus 20 mg/day OVA group and was similar to the number observed in mice administered 100 mg/day OVA (fig. 2d, e). Interestingly, oral administration of ATRA without OVA had little effect on AHR, airway eosinophilia, cytokine levels in BAL fluid, or goblet cell metaplasia (fig. 2). Oral administration of ATRA in combination with 100 mg/day OVA feeding had no additional effects on AHR and airway inflammation compared to 100 mg/day OVA feeding alone (data not shown).

A 250-μg dose of ATRA was selected based on a preliminary investigation. We investigated the dose depen-
dency of the effects of ATRA on AHR, airway inflammation and goblet metaplasia and found that 250 μg of ATRA was superior to 50 μg and 1,000 μg (online suppl. fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000437326).

Comparison of Lung and PP Foxp3-Positive Treg Expansion
Previous reports described the potency of Treg cell induction by RA in vitro and in vivo [17, 22, 23]. To investigate the expansion of Treg cells in the lungs, cells were harvested and stained for CD4, CD25 and Foxp3. As shown in figure 3a and b, the ratio of Foxp3+ Treg cells to the total count of CD4+ T cells was increased in the ATRA plus 20 mg/day OVA group as compared to the 20 mg/day OVA group or ATRA alone.

To determine the effects of combined OVA and ATRA treatment on the gut, cells were harvested from PPs of treated mice and stained for CD4, CD25 and Foxp3. The ratio of Foxp3+ Treg cells to the total count of CD4+ T cells was not significantly increased by the ATRA plus 20 mg/day OVA treatment as compared to the 20 mg/day OVA group or the group that received ATRA alone (fig. 3c, d).
To investigate whether CD4+ T cells had the potential to modify AHR and allergic airway inflammation, lung CD4+ T cells were transferred from mice that received either ATRA and 20 mg/day OVA or only 20 mg/day OVA to control mice sensitized with OVA; these animals then underwent additional OVA exposures. Transfer of these cells from mice exposed to ATRA and OVA suppressed AHR to MCh, whereas transfer from mice that received OVA alone did not suppress AHR as compared to PBS-treated mice (fig. 4a). The percentage of eosinophils in BAL fluid was decreased in recipients of lung CD4+ T cells from mice that received ATRA and OVA as compared to mice that only received OVA (fig. 4b). Transfer of lung CD4+ T cells from mice treated with ATRA and OVA suppressed IL-5 and IL-13 levels in BAL fluid (fig. 4c). Goblet cell metaplasia was dramatically reduced in recipients of lung CD4+ T cells from mice that received ATRA and OVA as compared to recipients of cells from mice that only received OVA (fig. 4d, e).

Effects of Lung CD4+ T Cell Transfer on AHR, Airway Inflammation and Airway Remodeling

To investigate whether CD4+ T cells had the potential to modify AHR and allergic airway inflammation, lung CD4+ T cells were transferred from mice that received either ATRA and 20 mg/day OVA or only 20 mg/day OVA to control mice sensitized with OVA; these animals then underwent additional OVA exposures. Transfer of these cells from mice exposed to ATRA and OVA suppressed AHR to MCh, whereas transfer from mice that received OVA alone did not suppress AHR as compared to PBS-treated mice (fig. 4a). The percentage of eosinophils in BAL fluid was decreased in recipients of lung CD4+ T cells from mice that received ATRA and OVA as compared to mice that only received OVA (fig. 4b). Transfer of lung CD4+ T cells from mice treated with ATRA and OVA suppressed IL-5 and IL-13 levels in BAL fluid (fig. 4c). Goblet cell metaplasia was dramatically reduced in recipients of lung CD4+ T cells from mice that received ATRA and OVA as compared to recipients of cells from mice that only received OVA (fig. 4d, e).
Effects of LE135 on AHR, Airway Inflammation and Airway Remodeling

To determine whether the effects of ATRA were mediated by the RAR, an antagonist of this receptor (LE135) was administered i.p. concomitantly with OVA and ATRA. As shown in figure 5a, LE135 reversed the inhibitory effects of ATRA. LE135 also increased the percentage of eosinophils and the levels of IL-5 and IL-13 in BAL fluid (fig. 5b, c). Goblet cell metaplasia was greater in mice that received LE135 with ATRA and OVA, as compared to those receiving ATRA and OVA only (fig. 5d, e). Moreover, the ratio of Foxp3+ Treg cells to the total count of CD4+ T cells was significantly decreased in the group that received LE135, OVA and ATRA, as compared to the group that only received OVA and ATRA (fig. 5f). In mice that received LE135 without ATRA and OVA, there was no significant change in AHR or airway eosinophilia (data not shown).

Discussion

The present study found that ATRA augmented the oral tolerance induced by OVA. LE135-mediated RAR blockade reversed the inhibitory effects of ATRA, indi-
cating the involvement of this receptor. We also demonstrated that the increase of lung Treg cells played a role, at least in part, in the suppression of AHR, airway eosinophilia and goblet cell metaplasia. This represented a novel approach to the investigation of the function of ATRA in a model of asthma.

In this study, oral administration of ATRA, in addition to OVA, enhanced the induction of oral tolerance. Orally administered ATRA may be absorbed in the gut mucosa and could subsequently modulate the immune system. Interestingly, our data suggested that the therapeutic effects of ATRA in this oral tolerance model required concomitant administration of antigen, because administration of ATRA without OVA had no effects on the therapeutic outcomes. It is presumably important for local antigen-presenting cells to recognize antigens under RA-rich milieu for upregulation of oral tolerance. Indeed, dendritic cells produce RA from dietary vitamin A using retinaldehyde dehydrogenase; they also express RAR and have been shown to respond to RA [24]. Moreover, intraperitoneal injection of ATRA in addition to oral OVA was reported to be ineffective for the amelioration of AHR and airway allergic inflammation because ATRA administered by this route appeared to be rapidly metabolized in the liver [25].

RA plays an indispensable role in the gut by modulating CD103+ dendritic cells [26, 27] and CD4+ T cells [16]. In particular, RA is known to be a strong inducer of Tregs, an effect mediated by enhanced TGF-β-driven phosphorylation of SMAD3 [28, 29], inhibition of CD4+CD44high memory T cells [30], or induction of histone H4 acetylation at the Foxp3 locus [31]. In this study, lung Tregs expressing CD4, CD25 and Foxp3 were increased by exposure to oral OVA, ATRA and subsequent aerosol OVA challenges; lung CD4+ T cells from mice treated with OVA and ATRA also sustained the suppression of AHR, airway inflammation and goblet cell metaplasia in mice sensitized and challenged with OVA. According to previous studies employing adoptive transfer of CD4+CD25+ T cells or administration of anti-CD25 antibody for the depletion of Tregs, naturally occurring and induced Treg cells both have the potential to modulate AHR and airway allergic inflammation [32–34]. In the present study, it was not technically possible to isolate adequate numbers of CD4+CD25+ cells and we therefore transferred the entire CD4+ cell population. Our data indicated that these CD4+ T cells were able to sustain the inhibitory effects on AHR and airway inflammation, suggesting that the CD4+ T cells transferred in the present study contained a sufficient number of regulatory features.

In our previous study, AHR and allergic inflammation were ameliorated through oral antigen-mediated induction of gut Treg cells, inhibited by endogenous and exogenous IL-17 [15]. Oral administration of ATRA with OVA was thought to induce gut Treg cells, which presumably moved to the lung after the antigen challenges. However, in the current study, the number of Treg cells in PPs was not significantly increased after oral administration of ATRA in addition to OVA feeding compared to OVA feeding alone. Although our results did not conclusively demonstrate that the Treg cells found in the lung originated in the gut, they showed that oral administration of ATRA in addition to OVA induced Treg cells in the lung after OVA challenges. Future work should be conducted to investigate the transfer of Treg cells using cells isolated from the gut.

Several reports have described the inhibitory effects of oral antigen administration on airway allergic inflammation [35, 36]. These studies involved the administration of antigen prior to the sensitization or challenge phases. Oral tolerance is difficult to induce after the establishment of a robust immune system; indeed, our data showed that a lower dose (20 mg/day) of oral OVA had much less effect on AHR, airway inflammation or goblet cell metaplasia than the higher dose (100 mg/day). However, as bronchial asthma patients never receive immunotherapy before the occurrence of their disease in the clinical setting, it is worth noting that the addition of ATRA could augment the effects of oral tolerance in this therapeutic model.

Although RA is involved in modulating the function and maturation of eosinophils [37], basophils [38] and mast cells [39], as well as dendritic cells and T cells, there are few reports describing its effects on airway allergic inflammation. Maret et al. [40] reported that systemic administration of liposome-encapsulated ATRA during the sensitization phase induced more sustained levels of RA (as compared with a conventional ATRA formulation); this augmented airway eosinophilia, the levels of Th2 cytokines and chemokines, and serum IgE levels. On the other hand, systemic administration of ATRA from immunization to the challenge phases ameliorated the inflammatory allergic inflammation by modulating Th2 differentiation [41]. In the present study, oral administration of ATRA concomitant to OVA augmented the oral tolerance. From previous reports, ATRA has multiple effects for allergic models, and this study represents a unique approach to investigating the novel functions of ATRA.

In summary, we investigated the role of ATRA in modulating the induction of oral tolerance in a murine airway allergy model. After challenges with OVA, we
evaluated AHR and allergic inflammation. We also investigated the modulating effects of CD4+ T cell transfer from mice that were treated with oral ATRA and/or OVA, and assessed whether the effects of ATRA were mediated through the RAR using LE135. These data suggested that oral administration of ATRA concomitant with antigen was useful for augmenting the effects of oral tolerance via the modulation of Treg cell induction in this murine asthma model.

Acknowledgements

The authors are grateful for the expert help of Dr. Naofumi Imai, Ms. Keiko Yamagiwa and Ms. Kaori Takahashi for performing the histological studies and caring for the animals.

Conflict of Interest

The authors declare that they have no competing interests.

References


